As biotechnology issues erupt inside the Beltway and beyond, the trade association known as BIO is increasingly under the microscope.
The controversy surrounding the development of the human DNA map, congressional inquiries into gene therapy experiments, and the regulatory and marketplace skirmishes over genetically modified foods has spurred business for the Biotechnology Industry Organization. A seven-year-old association, BIO has grown four-fold in the last few years and taken the lead on behalf of one of the economy’s most dynamic new forces.
